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A number of hormonal approaches for prevention of endometrial and breast cancers have been proposed. Because of the hormonal responsiveness
of both tumors, much attention has focused on effects of exogenous hormone use. Although estrogens in hormone replacement therapy increase
the risk of endometrial cancer, the disease is substantially reduced by long-term use of oral contraceptives. The issues with breast cancer are more
complex, mainly because of a variety of unresolved effects. Long-term estrogen use is associated with some increase in breast cancer risk, and
certain patterns of oral contraceptives appear to predispose to early-onset disease. With respect to estrogens, preventive approaches for both
tumors would include use for as limited periods of time as possible. Addition of a progestin appears to lower estrogen-associated endometrial
disease, but its effect on breast cancer risk remains less clear. Additional studies on effects of detailed usage parameters should provide useful
insights into etiologic mechanisms. Other preventive approaches for endometrial cancer that may work through hormonal mechanisms include
staying thin, being physically active, and maintaining a vegetarian diet. Breast cancer risk may possibly be reduced by extended periods of
breastfeeding, restriction of intake of alcoholic beverages, remaining thin later in life, and being physically active. Additional research is needed to
clarify the biologic mechanisms of these associations. The bridging of epidemiology with the biologic sciences should clarify many unresolved
issues and lead to better preventive approaches. - Environ Health Perspect 103(Suppl 8):185-189 (1995)
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Introduction
Both endometrial cancer and breast cancer
have been shown to be hormonally respon-
sive tumors. It is not surprising therefore
that these tumors are affected by both hor-
mone replacement therapy and oral contra-
ceptive usage. Thus, a major focus of the
present paper is on defining exogenous
hormonal relationships for these tumors.
Although much is known about their
effects, a number of unresolved issues
remain. Further information on effects
would be useful in terms ofpromoting bet-
ter recommendations for usage and clarify-
ing etiologic mechanisms. Prevention has
also been approached through alterations
in lifestyle factors, most of which are
thought to affect risk through hormonal
mechanisms. Ultimately, however, preven-
tion will depend on better understanding
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the biology of the tumors. Therefore, the
final section of this paper will focus on
future research priorities, which should
integrate epidemiology with biochemical
approaches.
Hormone replacement therapy consists
ofeither estrogen alone or estrogen com-
bined with a progestin. In the United
States, the most commonly used menopau-
sal hormones are conjugated equine estro-
gens and medroxyprogesterone acetate.
Their use may be either short-term or
long-term. Short-term use is for the relief
ofsymptoms at the time ofthe menopause
and may be for a few months or years.
Long-term use is intended to prevent
osteoporosis and fractures and cardiovascu-
lar diseases. To achieve maximum preven-
tive benefit, hormone use should be,
essentially, life-long. However, such usage
may be associated with some adverse
effects, including increased risk of both
endometrial and breast cancers.
Oral contraceptives are for the most
part combination products of an estrogen
plus a progestin. The estrogen is either
ethinyl estradiol or mestranol (the latter is
metabolized in the body to the former),
but the progestins are more varied. They
are derived from either the 17-hydroxy-
progesterone compounds (norethindrone
is a prototype) or the 19-nor testosterone
compounds. The latter have greater
androgenic activity than the former.
Since the relationship of hormones to
risk ofovarian and cervical cancers has been
addressed elsewhere (M Pike, personal com-
munication), the present review will focus
on cancers ofthe breast and endometrium.
However, it is worth noting that the risk of
ovarian cancer can be substantially reduced
by long-term use oforal contraceptives (1).
Effects of hormones on cervical cancer
remain less clear (2) because little research
has been conducted on menopausal hor-
mone relationships. More research has been
conducted on the etiologic role oforal con-
traceptives, and some studies show that
long-term use increases the risk ofinvasive
cervical cancer. However, in the United
States, where cervical cytology is commonly
used, the precursor lesions are usually iden-
tified and treated well before invasive cancer
develops. The possible risk ofcervical can-
cer from oral contraceptives (or from any
other cause) can essentially be eliminated
with regular (every 1 to 3 years) cervical
cytologic screening.
Endometrial Cancer
It has been well demonstrated that estro-
gens cause endometrial cancer at the doses
normally consumed for either acute symp-
toms or long-term prevention. The effect is
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duration dependent; i.e., longer use confers
greater risk (3-5). Ten years ofuse can pro-
duce an 8- to 10-fold increase in risk. In
some studies, cessation ofuse appears to be
associated with a relatively rapid decrease in
risk, although other studies suggest that ele-
vated risk may continue for some time after
discontinuation (3-5). In general, the dis-
ease produced is not an extremely aggressive
cancer (6,7), but mortality, nonetheless,
appears elevated (8).
Progestins have been shown to produce
regressive changes in endometrial hyperpla-
sia, a presumed precursor ofendometrial
cancer (9). This has led to widespread
enthusiasm for combining estrogen therapy
with progestins to combat carcinogenic
effects. Although lower rates ofendome-
trial hyperplasia have been seen among
those receiving combined therapy than
among women receiving estrogens alone,
effects on endometrial cancer remain less
clear. In one recent study (10), the addition
of a progestin for 10 or more days each
month considerably reduced endometrial
cancer risk. Whether or not the risk associ-
ated with estrogens may be completely
obliterated by the addition of progestins
remains unresolved.
The situation with oral contraceptives
and endometrial cancer is quite clear. Oral
contraceptives reduce the risk ofendome-
trial cancer, with the greatest benefit occur-
ring among long-term users, whose risk is
reduced by approximately half that of
nonusers (11-14). Some studies have
shown that this risk reduction persists for
at least 5 years after cessation ofpill usage
(13), although other studies have found
that the protective effect wanes within 3
years (14).
Breast Cancer
The issues with breast cancer are much
more complex, since contradictory rela-
tionships have been derived from a number
of diverse studies. Resolution ofeffects is
especially important, since breast cancer is
a very common disease and the mortality
is high.
Because ofthe conflicting results, it is
difficult to determine precise relationships
with hormone use. However, it would
appear from several studies that use oforal
contraceptives may be associated with a
relative risk ofabout 1.5 for breast cancers
diagnosed at an early age (i.e., before age
45) (15-18). This excess risk appears to
result from high risks among recent users
and among women who either start using
oral contraceptives at young ages (e.g.,
before age 20) or who use them for long
periods (e.g., 8 years or more). Other oral
contraceptive use characteristics and use by
older women do not produce this increased
risk as best as can be determined from
available data.
Although there is contradictory evi-
dence regarding the effect ofestrogens on
breast cancer risk, a number ofstudies sug-
gest that long-term use (10 years or more)
may result in increased relative risks ofthe
magnitude of 1.4 to 1.8 (19-24). Some
data suggest that current use may also be
adverse (24-26), but many studies do not
support such an effect. The effect ofcom-
bined estrogen/progestin therapy is less cer-
tain because the experience in the United
States with that regimen has not been suffi-
ciendy long (27). Data in this country are
just now accumulating. However, unlike
the endometrium, where progestins coun-
teract the proliferative effects ofestrogens,
there is evidence that progestins cause
mitogenic activity in breast tissue. Thus,
there is reason to suspect that combined
therapy may have very different effects on
breast cancer risk than on endometrial can-
cer risk. In support ofthis are data from a
Swedish study, in which the combined
therapy was associated with more adverse
effects than with estrogens alone (28).
Additional studies in this country are
needed to confirm the effects ofthis mode
oftherapy, which has become increasingly
popular in recent times.
Prevention
Much attention has focused on preventing
these cancers. More is known about pre-
venting endometrial cancer than breast
cancer, mainly because ofthe recognized
importance ofestrogens in the etiology of
endometrial disease.
For endometrial cancer, one recom-
mendation is quite straightforward;
namely, menopausal estrogens should not
be used. If hormones must be used, they
should be used with at least 10 days of a
progestin each month; up to 13 days may
be better. Data arejust beginning to emerge
on the currently popular regimen ofcon-
tinuous, daily, low-dose estrogen plus
progestin (29), but effects on either endo-
metrial or breast cancer remain unresolved.
Additionally, since obesity is a well-
recognized riskfactorforendometrial cancer,
staying thin is a preventive approach. This
riskfactor is also thought to operate through
an estrogenic mechanism, since after
menopause the primary source ofestrogens
is from conversion ofandrostenedione to
estrone in adipose tissue. Obesity is also
associated with higher conversion rates or
elevated plasma levels ofestrogen. Further,
obesity is related to lower levels of sex
hormone-binding globulin and more fre-
quent anovulatory menstrual cycles (less
progesterone). Dietary modification may
also be effective in reducing the risk of
endometrial cancer. Studies ofvegetarians
provide evidence that risk may be affected
by modification in hormone metabolism.
Thus, postmenopausal vegetarian women
have been found to have lower urine levels
ofestriol and total estrogens, lower plasma
prolactin levels, and higher serum values of
sex hormone-binding globulin than non-
vegetarian women (30). In line with evi-
dence ofeffects on endometrial cancer risk
ofobesity and dietary patterns are recent
data supporting a possible protective effect
ofphysical activity (31). The relationship
is biologically plausible, since physical inac-
tivity is known to be involved in the devel-
opment and maintenance of excess body
weight. Further, inactive women have been
shown to have higher serum estrogen levels
than active women, even after taking dif-
ferences in body weight into account (32).
Finally, it is apparent that the risk ofendo-
metrial cancer can be lowered by certain
childbearing patterns, since there are exten-
sive data showing a low risk for women
bearing many children and a high risk for
nulliparous women. It is as yet unclear
whether the biologic mechanism underly-
ing the association with childbearing relates
to changes in endogenous hormones.
The hormonally relevant strategies to
prevent breast cancer are more complex
than those for endometrial cancer. Although
there are data to suggest that use oforal
contraceptives at young ages or for long
periods of time may be associated with
some increase in risk, it appears that these
usage characteristics may apply only to an
increase in risk for a minority ofbreast can-
cers; namely, those occurring at young ages.
Thus, these restricted risks must beweighed
against recognized benefits oforal contra-
ceptives in terms ofpregnancy prevention
and reduction ofother diseases, including
not only endometrial cancer but also ovar-
ian cancer. Recommendations regarding the
effects of use of estrogens are somewhat
more clear and there is evidence that these
agents should not be used for long periods
of time. This recommendation results in
the need to balance the risk ofosteoporosis
and cardiovascular diseases against breast
cancer. There are many reviews evaluating
the risk/benefit and cost effectiveness of
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menopausal estrogen therapy (33-36). In
all ofthese assessments, mortality from car-
diovascular diseases outweighed the risk of
death from breast cancer, although in some
ofthe analyses the benefits may have been
overstated because ofselective use ofestro-
gens by healthier women. Further, it is
doubtful that these analyses fully describe
the situation, since many women would
rather not face an increase in breast cancer
risk, even ifit means increasing their risk of
aheart attack on alarger scale.
Other therapeutic regimens that may
alter breast cancer risk through hormonal
mechanisms have received increasing
enthusiasm. However, the proposed regi-
mens are controversial and are currently
being recommended as preventive agents in
only very high-risk women. These include
tamoxifen, which is currently being tested
in a clinical trial among high-risk women
(37). Tamoxifen is an antiestrogenic agent
that has been shown in therapeutic trials to
reduce the incidence of new primary can-
cers in the unaffected breast. Although the
current status of this trial is uncertain
because ofobserved increases in the occur-
rence of endometrial cancer among
exposed women, the resolution ofthe pre-
ventive effect ofthis intervention on breast
cancer risk is ofgreat importance. Also of
interest is the preventive effect of
gonadotropin-releasing hormone agonists
that are currently being tested as a possible
preventive agent among younger women
(38). The long-term effects of both of
these agents, however, must be tested in
large, randomized, controlled intervention
trials before they can be introduced for
general use.
There are a number ofwell-established
risk factors for breast cancer, but most are
not readily amenable to preventive mecha-
nisms. These include higher risks for
women with early ages at menarche, late
ages at menopause, late ages at first birth, a
family history ofbreast cancer, and a his-
tory ofbenign breast disease. In terms of
preventable factors, much attention has
focused on possible dietary means oflower-
ing risk, but most studies to date have
yielded inconclusive findings (39). Restric-
tion ofalcoholic beverage consumption is
generally viewed as beneficial, although
controversy still exists regarding whether
the association is causal. Further, the levels
ofconsumption associated with risk remain
to be elucidated. There is, however, fairly
convincing evidence that obesity somewhat
increases the risk ofpostmenopausal breast
cancer. Despite this, there has been a
surprising lack ofattention on weight loss
as an interventive technique for lowering
breast cancer risk. This may result from the
complexities associated with body mass as a
predictor ofbreast cancer risk, since large
body mass has actually been associated with
a reduction in the risk ofearly-onset breast
cancer, possibly due to high levels ofprog-
esterone in thin, premenopausal women.
Further complicating the interpretation of
the role ofanthropometric factors in the
etiology ofbreast cancer is that the timing
ofweight change as well as the distribution
offat on the body has been shown to be
predictive of risk (40,41). Several studies
have emphasized the importance ofchange
in recent weight, possibly reflecting its role
in adult adiposity. There is also accumulat-
ing evidence that fat distribution may
predict breast cancer risk among postmeno-
pausal women, with abdominal obesity
being more hazardous than peripheral accu-
mulation. Further, recent results support
the possible importance ofphysical activity
in preventing breast cancer (42). Adoles-
cent physical activity has been shown to be
particularly important in reducing risk, pos-
sibly through a delay in the onset ofmenar-
che. Thus, the interrelationships ofbody
size, diet, and physical activity obviously
merit further research. Finally, recent atten-
tion has focused on avoidance ofcertain
environmental factors (most notably, pesti-
cide residues) (43) as a means ofbreast can-
cer prevention, although much further
research is needed to clarify how risk might
be affected.
Like endometrial cancer, breast cancer
has been shown to be influenced by repro-
ductive patterns. The age at first birth has
been shown in many studies to be an
important determinant ofrisk. Since this is
not a readily modifiable lifestyle factor, it is
encouraging that recent studies are show-
ing some consistency regarding a protective
effect ofbreastfeeding on breast cancer risk
(44,45). However, some studies support
that breastfeeding may only protect against
premenopausal breast cancer, and it
remains unclear whether the limited dura-
tions ofbreastfeeding of most women in
the United States will be sufficient to alter
breast cancer risk. Nonetheless, given the
widespread potential for this intervention,
it is obvious that further exploration ofits
preventive mechanisms regarding breast
cancer should be pursued.
Future Research
To be successful in gaining newinformation
for prevention, our research strategies must
change. We should increase our efforts
in molecular/biochemical epidemiology.
This field combines rigorous epidemio-
logic study designs with the technology
and innovation of molecular biology.
Molecular epidemiology allows for study
of cellular and molecular alterations in
somatic tissue (the target tissue for cancer)
and in germline tissue. In somatic tissue,
there are opportunities to study markers in
precursor lesions or in cancer tissue.
Precursor lesions are ofparticular interest
in etiology and pathogenesis. Markers
found in precursor lesions can be related to
those identified in invasive cancers as well
as to hormonal interventions and other risk
factors identified through more traditional
epidemiologic methods.
Endogenous hormones represent a bio-
marker that is being increasingly examined
with respect to the etiology ofendometrial
and breast cancers. Endometrial cancer is a
particularly appropriate cancer to approach
from a biochemical/epidemiologic perspec-
tive, since there is such clear evidence of
the influence ofovarian hormones on risk.
A unified theory ofhow risk factors might
operate through one common hormonal
pathway has been suggested (Figure 1)
(46). It is apparent, therefore, that many
ofthe risk factors produce higher levels of
estrogen exposure without the compen-
satory effects of progesterone. However,
there are many important gaps in our
knowledge that inhibit a full understand-
ing of the proposed carcinogenic process.
Integration ofbiochemical markers with
epidemiologic risk factors may help to
answer a number ofimportant unresolved
questions. For instance, mechanisms of
action ofdietary factors, body fat distribu-
tion, and physical activity may be better
understood by correlating these risk factors
with patterns ofendogenous hormones.
From cancer tissue, homogeneous case
groups can be defined byspecific alterations
analogous to the concept ofuniform histo-
logic case groups and exposures ofinterest
can be examined within each subgroup.
This approach can provide means ofidenti-
fying molecular signatures ofmany types of
exposures and the definitive evidence
needed to clarify cause-and-effect relation-
ships. For instance, in breast cancer, one
approach to differentiating disease has been
to examine risk factors by estrogen receptor
status. Most studies that have evaluated
prior estrogen use by estrogen receptor sta-
tus have found no significant differences,
although several studies showed that estro-
gen users were more likely to have estrogen
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Figure 1. Riskfactors for endometrial cancer and their possible modes ofaction.
receptor-negative tumors (47-49). These
studies, however, by only considering estro-
gen receptor status and not also proges-
terone receptor status, may have missed
distinctive relationships. Thus, future stud-
ies that precisely define breast cancer by a
variety ofbiologic parameters may provide
further insights into hormonal mechanisms
ofcarcinogenesis.
Germline tissue provides a different
kind of information and has a different
import for epidemiologic studies. The
DNA from germline tissue can provide
evidence of genetic alterations that may
enhance susceptibility to cancer or other
diseases. White blood cells frequently are
analyzed for susceptibility markers because
they are reasonably accessible. Through
analysis of cellular and molecular alter-
ations in germline tissue, we can study the
interaction of susceptibility markers and
epidemiologic risk factors such as hor-
monal exposures for their combined effect
on cancer risk. With respect to breast
cancer, identification of the BRCA-1 and
p53 tumor suppressor genes holds promise
as a potential modifier of other, more
traditional risk factors.
For epidemiologists to join forces with
laboratory scientists, a significant amount
of bridging work is needed. This requires
transitional epidemiologic studies that
employ biochemical or molecular markers
from human tissues or fluids and that
bridge the gap between innovative labora-
tory technology and assays that can be
used in population-based epidemiologic
research. These studies address laboratory
issues ofquality control, assay accuracy and
replicability within and across laboratories,
feasibility, and standardization. The epi-
demiologic issues concern tissue collection
acceptable to subjects, and specimen trans-
port and storage consistent with the needs
ofthe laboratory. Unless time is devoted to
these types ofstudies, we will have many
failures and waste significant amounts of
scientific energy and resources.
Last, attention must be focused on
translational research. The synthesis of
knowledge from multiple scientific disci-
plines to develop and undertake a research
agenda should bring us closer to solving
problems than would be achieved merely
byapproaching issues through the vision of
a singular discipline. It is also the rationale
for and means by which the prevention
trials ofpromising strategies and agents can
be designed and operationalized. The
potential for application ofresearch find-
ings to the reduction ofhuman cancer inci-
dence must be an important criterion for
our research agenda.
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